Tonix Pharmaceuticals Announces Issuance of U.S. Patent for the Composition and Formulation of TNX-102 SL July 25, 2019 • 7:00 AM EDT
Tonix Pharmaceuticals Announces Closing of Public Offering of Common Stock July 18, 2019 • 4:05 PM EDT
Tonix Pharmaceuticals Announces Pricing of Public Offering of Common Stock July 16, 2019 • 8:30 AM EDT
Tonix Pharmaceuticals Announces Issuance of Patent in China for the Composition and Formulation of TNX-102 SL June 13, 2019 • 7:00 AM EDT
Tonix Pharmaceuticals Presented Results from Pharmacokinetic Analyses of TNX-102 SL in a Poster Presentation at the American Society of Clinical Psychopharmacology May 30, 2019 • 8:00 AM EDT
Tonix Pharmaceuticals Expands Pipeline with Mid-Stage Biologic Candidate TNX-1300 for Cocaine Intoxication May 23, 2019 • 7:00 AM EDT
Tonix Pharmaceuticals to Speak at the Second Chance Digital Impact Recipient Gala May 22, 2019 • 4:19 PM EDT
Tonix Pharmaceuticals Will Present Results from Pharmacokinetic Analyses of TNX-102 SL in a Poster Presentation at the American Society of Clinical Psychopharmacology May 21, 2019 • 4:15 PM EDT